spacer
spacer

PDBsum entry 6fiv

Go to PDB code: 
protein ligands links
Hydrolase/hydrolase inhibitor PDB id
6fiv

 

 

 

 

Loading ...

 
JSmol PyMol  
Contents
Protein chain
112 a.a. *
Ligands
SO4
3TL
Waters ×76
* Residue conservation analysis
PDB id:
6fiv
Name: Hydrolase/hydrolase inhibitor
Title: Structural studies of HIV and fiv proteases complexed with an efficient inhibitor of fiv pr
Structure: Retropepsin. Chain: a. Engineered: yes. Other_details: complexed with tl-3-093
Source: Feline immunodeficiency virus. Organism_taxid: 11674. Strain: (isolate petaluma). Expressed in: escherichia coli. Expression_system_taxid: 562
Biol. unit: Dimer (from PQS)
Resolution:
1.90Å     R-factor:   0.155     R-free:   0.266
Authors: M.Li,T.Lee,G.Morris,G.Laco,C.Wong,A.Olson,J.Elder,A.Wlodawer, A.Gustchina
Key ref:
M.Li et al. (2000). Structural studies of FIV and HIV-1 proteases complexed with an efficient inhibitor of FIV protease. Proteins, 38, 29-40. PubMed id: 10651036 DOI: 10.1002/(SICI)1097-0134(20000101)38:1<29::AID-PROT4>3.0.CO;2-N
Date:
02-Dec-98     Release date:   09-Dec-98    
PROCHECK
Go to PROCHECK summary
 Headers
 References

Protein chain
Pfam   ArchSchema ?
P16088  (POL_FIVPE) -  Pol polyprotein from Feline immunodeficiency virus (isolate Petaluma)
Seq:
Struc:
 
Seq:
Struc:
 
Seq:
Struc:
1124 a.a.
112 a.a.*
Key:    PfamA domain  Secondary structure  CATH domain
* PDB and UniProt seqs differ at 1 residue position (black cross)

 Enzyme reactions 
   Enzyme class 2: E.C.2.7.7.-  - ?????
[IntEnz]   [ExPASy]   [KEGG]   [BRENDA]
   Enzyme class 3: E.C.2.7.7.49  - RNA-directed Dna polymerase.
[IntEnz]   [ExPASy]   [KEGG]   [BRENDA]
      Reaction: DNA(n) + a 2'-deoxyribonucleoside 5'-triphosphate = DNA(n+1) + diphosphate
DNA(n)
+ 2'-deoxyribonucleoside 5'-triphosphate
= DNA(n+1)
+ diphosphate
   Enzyme class 4: E.C.3.1.-.-
[IntEnz]   [ExPASy]   [KEGG]   [BRENDA]
   Enzyme class 5: E.C.3.1.13.2  - exoribonuclease H.
[IntEnz]   [ExPASy]   [KEGG]   [BRENDA]
      Reaction: Exonucleolytic cleavage to 5'-phosphomonoester oligonucleotides in both 5'- to 3'- and 3'- to 5'-directions.
   Enzyme class 6: E.C.3.1.26.13  - retroviral ribonuclease H.
[IntEnz]   [ExPASy]   [KEGG]   [BRENDA]
   Enzyme class 7: E.C.3.4.23.-  - ?????
[IntEnz]   [ExPASy]   [KEGG]   [BRENDA]
   Enzyme class 8: E.C.3.6.1.23  - dUTP diphosphatase.
[IntEnz]   [ExPASy]   [KEGG]   [BRENDA]
      Reaction: dUTP + H2O = dUMP + diphosphate + H+
dUTP
+ H2O
= dUMP
+ diphosphate
+ H(+)
Note, where more than one E.C. class is given (as above), each may correspond to a different protein domain or, in the case of polyprotein precursors, to a different mature protein.
Molecule diagrams generated from .mol files obtained from the KEGG ftp site

 

 
    reference    
 
 
DOI no: 10.1002/(SICI)1097-0134(20000101)38:1<29::AID-PROT4>3.0.CO;2-N Proteins 38:29-40 (2000)
PubMed id: 10651036  
 
 
Structural studies of FIV and HIV-1 proteases complexed with an efficient inhibitor of FIV protease.
M.Li, G.M.Morris, T.Lee, G.S.Laco, C.H.Wong, A.J.Olson, J.H.Elder, A.Wlodawer, A.Gustchina.
 
  ABSTRACT  
 
Three forms of feline immunodeficiency virus protease (FIV PR), the wild type (wt) and two single point mutants, V59I and Q99V, as well as human immunodeficiency virus type 1 protease (HIV-1 PR), were cocrystallized with the C2-symmetric inhibitor, TL-3. The mutants of FIV PR were designed to replace residues involved in enzyme-ligand interactions by the corresponding HIV-1 PR residues at the structurally equivalent position. TL-3 shows decreased (improved) inhibition constants with these FIV PR mutants relative to wt FIV PR. Despite similar modes of binding of the inhibitor to all PRs (from P3 to P3'), small differences are evident in the conformation of the Phe side chains of TL-3 at the P1 and P1' positions in the complexes with the mutated FIV PRs. The differences mimick the observed binding of TL-3 in HIV-1 PR and correlate with a significant improvement in the inhibition constants of TL-3 with the two mutant FIV PRs. Large differences between the HIV-1 and FIV PR complexes are evident in the binding modes of the carboxybenzyl groups of TL-3 at P4 and P4'. In HIV-1 PR:TL-3, these groups bind over the flap region, whereas in the FIV PR complexes, the rings are located along the major axis of the active site. A significant difference in the location of the flaps in this region of the HIV-1 and FIV PRs correlates with the observed conformational changes in the binding mode of the peptidomimetic inhibitor at the P4 and P4' positions. These findings provide a structural explanation of the observed Ki values for TL-3 with the different PRs and will further assist in the development of improved inhibitors.
 
  Selected figure(s)  
 
Figure 4.
Figure 4. Superposition of the crystal structures of wt FIV PR (blue) and its two mutants, V59I (yellow) and Q99V (purple), complexed with TL-3, near the S1 binding site. Water molecules are shown as spheres, whereas hydrogen bonds are shown as dotted lines.
Figure 6.
Figure 6. Comparison of the interface between the flap region and loop 93-98 (76-81) in wt FIV PR (blue) and HIV-1 PR (pink).
 
  The above figures are reprinted by permission from John Wiley & Sons, Inc.: Proteins (2000, 38, 29-40) copyright 2000.  
  Figures were selected by an automated process.  

Literature references that cite this PDB file's key reference

  PubMed id Reference
  17212810 H.Heaslet, Y.C.Lin, K.Tam, B.E.Torbett, J.H.Elder, and C.D.Stout (2007).
Crystal structure of an FIV/HIV chimeric protease complexed with the broad-based inhibitor, TL-3.
  Retrovirology, 4, 1.
PDB code: 2hah
16873240 Y.C.Lin, A.Brik, A.de Parseval, K.Tam, B.E.Torbett, C.H.Wong, and J.H.Elder (2006).
Altered gag polyprotein cleavage specificity of feline immunodeficiency virus/human immunodeficiency virus mutant proteases as demonstrated in a cell-based expression system.
  J Virol, 80, 7832-7843.  
15934050 A.Brik, J.Alexandratos, Y.C.Lin, J.H.Elder, A.J.Olson, A.Wlodawer, D.S.Goodsell, and C.H.Wong (2005).
1,2,3-triazole as a peptide surrogate in the rapid synthesis of HIV-1 protease inhibitors.
  Chembiochem, 6, 1167-1169.
PDB codes: 1zp8 1zpa
15333937 M.Sanches, N.H.Martins, A.Calazans, R.d.e. .M.Brindeiro, A.Tanuri, O.A.Antunes, and I.Polikarpov (2004).
Crystallization of a non-B and a B mutant HIV protease.
  Acta Crystallogr D Biol Crystallogr, 60, 1625-1627.  
14517908 A.Nayeem, S.Krystek, and T.Stouch (2003).
An assessment of protein-ligand binding site polarizability.
  Biopolymers, 70, 201-211.  
12767979 Y.C.Lin, Z.Beck, G.M.Morris, A.J.Olson, and J.H.Elder (2003).
Structural basis for distinctions between substrate and inhibitor specificities for feline immunodeficiency virus and human immunodeficiency virus proteases.
  J Virol, 77, 6589-6600.  
11533212 B.Bühler, Y.C.Lin, G.Morris, A.J.Olson, C.H.Wong, D.D.Richman, J.H.Elder, and B.E.Torbett (2001).
Viral evolution in response to the broad-based retroviral protease inhibitor TL-3.
  J Virol, 75, 9502-9508.  
11206463 C.C.Mak, V.D.Le, Y.C.Lin, J.H.Elder, and C.H.Wong (2001).
Design, synthesis, and biological evaluation of HIV/FIV protease inhibitors incorporating a conformationally constrained macrocycle with a small P3' residue.
  Bioorg Med Chem Lett, 11, 219-222.  
11533208 Z.Q.Beck, Y.C.Lin, and J.H.Elder (2001).
Molecular basis for the relative substrate specificity of human immunodeficiency virus type 1 and feline immunodeficiency virus proteases.
  J Virol, 75, 9458-9469.  
10775609 Y.C.Lin, Z.Beck, T.Lee, V.D.Le, G.M.Morris, A.J.Olson, C.H.Wong, and J.H.Elder (2000).
Alteration of substrate and inhibitor specificity of feline immunodeficiency virus protease.
  J Virol, 74, 4710-4720.  
The most recent references are shown first. Citation data come partly from CiteXplore and partly from an automated harvesting procedure. Note that this is likely to be only a partial list as not all journals are covered by either method. However, we are continually building up the citation data so more and more references will be included with time. Where a reference describes a PDB structure, the PDB code is shown on the right.

 

spacer

spacer